Tamara P. Miller
YOU?
Author Swipe
View article: Optimizing high-dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia
Optimizing high-dose methotrexate treatment regimens to improve exposure and mitigate toxicity in infant patients with acute lymphoblastic leukemia Open
Introduction: High-dose methotrexate (HDMTX) is a key component of therapy for high risk acute lymphoblastic leukemia (ALL). Typical dosing regimens infuse 5 g/m2 over 24 hours in pediatric and adolescent young adult (AYA) patients without…
View article: Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity
Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia: The mediating roles of relapse and salvage chemotherapy intensity Open
Background Treatment for pediatric acute myeloid leukemia (AML) involves intensive anthracycline (ATC)-based chemotherapy, with cardiotoxicity being a common complication. While early cardiotoxicity has been associated with worse overall s…
View article: Association of race and ethnicity and incidence and severity of hyperglycemia and clinically-treated hypertension during induction therapy for pediatric acute lymphoblastic leukemia
Association of race and ethnicity and incidence and severity of hyperglycemia and clinically-treated hypertension during induction therapy for pediatric acute lymphoblastic leukemia Open
Background: Anti-cancer therapies used to treat pediatric acute lymphoblastic leukemia (ALL) achieve high cure rates but can cause significant adverse events (AEs), including hyperglycemia and hypertension. Development of these cardiovascu…
View article: Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1
Optimization of induction chemotherapy in pediatric patients with Acute Myeloid Leukemia: Real-world evidence to support removal of etoposide from induction 1 Open
Introduction: Induction chemotherapy for pediatric AML has historically used cytarabine, daunorubicin and etoposide (ADE). However, etoposide likely increases toxicity, and adult data suggest that ADE does not improve survival outcomes ove…
View article: What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High‐Dose Methotrexate Use in Pediatric Malignancies Open
High‐dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Theref…
View article: Erratum: Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR
Erratum: Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR Open
View article: 633. Incidence and Outcomes of Pediatric Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients Under Surveillance and Not Under Surveillance for Human Adenovirus (HAdV) in the Post-HCT Period
633. Incidence and Outcomes of Pediatric Allogeneic Hematopoietic Cell Transplant (allo-HCT) Recipients Under Surveillance and Not Under Surveillance for Human Adenovirus (HAdV) in the Post-HCT Period Open
Background Human Adenovirus (HAdV) can cause life-threatening illness in pediatric allo-HCT recipients, but studies to define incidence and outcomes of HAdV in allo-HCT patients are limited. Use of PCR-based HAdV surveillance varies by HCT…
View article: Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions
Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions Open
Introduction While clinical practice guidelines (CPGs) for pediatric oncology infection prophylaxis and management exist, few data describe actual management occurring at pediatric oncology centers. Methods An electronic survey querying in…
View article: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children Open
Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or higher risk of relapse significantly improved disease-free survival. (Funded by the National Institutes of He…
View article: Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR
Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR Open
PURPOSE Although the potential transformative effect of electronic health record (EHR) data on clinical research in adult patient populations has been very extensively discussed, the effect on pediatric oncology research has been limited. …
View article: Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies
Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies Open
Background Pediatric allogeneic hematopoietic cell transplant (allo‐HCT) recipients are at risk for morbidity and mortality from human adenovirus (HAdV). HAdV can be detected in an asymptomatic state, referred to as infection or with signs…
View article: An Interpretable Machine Learning Framework for Rare Disease: A Case Study to Stratify Infection Risk in Pediatric Leukemia
An Interpretable Machine Learning Framework for Rare Disease: A Case Study to Stratify Infection Risk in Pediatric Leukemia Open
Background: Datasets on rare diseases, like pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), have small sample sizes that hinder machine learning (ML). The objective was to develop an interpretable ML framewor…
View article: Missing the mark? Exploratory analysis of the 10‐year‐old cutoff as an independent marker of high‐risk disease in pediatric B‐ALL
Missing the mark? Exploratory analysis of the 10‐year‐old cutoff as an independent marker of high‐risk disease in pediatric B‐ALL Open
This single‐center, retrospective study evaluated age as a risk factor for relapsed/refractory disease and/or death in 153 children with B‐cell acute lymphoblastic leukemia. The study sample included children near the 10‐year age cutoff fo…
View article: Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment Open
Adolescents and young adults (AYAs; ages 15-39 years) with acute lymphoblastic leukemia (ALL) have worse outcomes than pediatric patients with ALL. Multiple factors contribute to this differential survival. AYAs are more likely to have hig…
View article: Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer
Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer Open
PURPOSE The optimal management of fever without severe neutropenia (absolute neutrophil count [ANC] ≥500/µL) in pediatric patients with cancer is undefined. The previously proposed Esbenshade Vanderbilt (EsVan) models accurately predict ba…
View article: Supportive Care in Pediatric Oncology: Opportunities and Future Directions
Supportive Care in Pediatric Oncology: Opportunities and Future Directions Open
The optimization of outcomes for pediatric cancer patients relies on the successful advancement of supportive care to ease the treatment burden and mitigate the long-term impacts of cancer therapy. Advancing pediatric supportive care requi…
View article: Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia
Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia Open
We evaluated disparities in disease burden, organ dysfunction, vital signs, and timing of therapy in children newly presenting with acute leukemia. Among 899 patients with acute leukemia diagnosed at two large children's hospitals, a prior…
View article: Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN)
Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN) Open
Children with acute leukemia are at increased risk of kidney injury. Using electronic health record data from three centers between 2010 and 2018, this study retrospectively described acute kidney injury (AKI) and chronic kidney disease (C…
View article: Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org Open
The MTXPK.org webtool was launched in December 2019 and was developed to facilitate model‐informed supportive care and optimal use of glucarpidase following the administration of high‐dose methotrexate (HDMTX). One limitation identified du…
View article: High burden of clinically significant adverse events associated with contemporary therapy for pediatric T‐cell acute lymphoblastic leukemia/lymphoma
High burden of clinically significant adverse events associated with contemporary therapy for pediatric T‐cell acute lymphoblastic leukemia/lymphoma Open
Background Despite improvements in survival for children with T‐cell acute lymphoblastic leukemia and lymphoma (T‐ALL/LLy), morbidity remains high. However, data are lacking regarding comprehensive descriptions of clinically relevant adver…
View article: Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care
Children's Oncology Group's 2023 blueprint for research: Cancer control and supportive care Open
The objective of the Cancer Control and Supportive Care (CCL) Committee in the Children's Oncology Group (COG) is to reduce the overall morbidity and mortality of therapy‐related toxicities in children, adolescents, and young adults with c…
View article: SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731
SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731 Open
Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID‐19) in adults; however, data specific to children with leukemia are limited. High‐quality infectious adverse event data from the ongoing Children's Oncology…
View article: Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database
Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database Open
Background Administrative datasets are useful for identifying rare disease cohorts such as pediatric acute myeloid leukemia (AML). Previously, cohorts were assembled using labor‐intensive, manual reviews of patients’ longitudinal chemother…
View article: Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders Open
Background Pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorder [EBV(−)M‐PTLD] comprises approximately 10% of M‐PTLD. No large multi‐institutional pediatric‐specific reports on treatmen…
View article: Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric <scp>PTLD</scp> collaborative
Burkitt lymphoma after solid‐organ transplant: Treatment and outcomes in the paediatric <span>PTLD</span> collaborative Open
Summary Burkitt lymphoma arising in paediatric post‐solid‐organ transplantation‐Burkitt lymphoma (PSOT‐BL) is a clinically aggressive malignancy and a rare form of post‐transplant lymphoproliferative disorder (PTLD). We evaluated 35 patien…
View article: Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy
Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy Open
Background An adequate absolute lymphocyte count (ALC) is an essential first step in autologous chimeric antigen receptor (CAR) T‐cell manufacturing. For patients with acute myelogenous leukemia (AML), the intensity of chemotherapy receive…
View article: Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials Open
Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported o…
View article: Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia
Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia Open
Background Infections cause significant treatment‐related morbidity during pediatric acute lymphoblastic leukemia/lymphoma (ALL/LLy) therapy. Fevers during periods without severe neutropenia are common, but etiologies are not well‐describe…
View article: Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group
Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group Open
Infections cause substantial morbidity for children with acute lymphoblastic leukemia (ALL). Therefore, accurate characterization of infectious adverse events (AEs) reported on clinical trials is imperative to defining, comparing, and mana…
View article: Automated Ascertainment of Typhlitis From the Electronic Health Record
Automated Ascertainment of Typhlitis From the Electronic Health Record Open
PURPOSE Adverse events (AEs) on Children's Oncology Group (COG) trials are manually ascertained using Common Terminology Criteria for Adverse Events. Despite significant effort, we previously demonstrated that COG typhlitis reporting sensi…